Beaulieu Sylvain, Kinahan Paul, Tseng Jeffrey, Dunnwald Lisa K, Schubert Erin K, Pham Pam, Lewellen Barbara, Mankoff David A
Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA.
J Nucl Med. 2003 Jul;44(7):1044-50.
The purpose of this study was to measure how (18)F-FDG PET standardized uptake values (SUVs) change over time in breast cancer and to examine the feasibility of a method to adjust for modest variations in the time of uptake measurement experienced in clinical practice.
(18)F-FDG PET was performed as 60-min dynamic imaging with an additional image acquired at approximately 75 min after injection. For 20 newly diagnosed, untreated, locally advanced breast cancer patients, both the maximum SUV and the average SUV within the lesion were calculated with and without correction for blood glucose concentration. A linear regression analysis of the portion of the time-activity curves starting at 27 min after injection was used to estimate the rate of SUV change per minute during the interval from 27 to 75 min. The rate of SUV change with time was compared with the instantaneous SUV obtained at different times from 27 to 75 min.
In untreated breast cancer, (18)F-FDG SUV values changed approximately linearly after 27 min at a rate ranging from -0.02 to 0.15 per minute. In addition, the rate of SUV change was linearly correlated with the instantaneous SUV measured at different times after injection (r(2) ranged from 0.82 to 0.94; P < 0.001). Using this information, an empirical linear model of SUV variation with time from injection to uptake measurement was formulated. The comparison method was then applied prospectively to a second set of 20 locally advanced breast cancer lesions not included in the initial analysis. The average percent error using the method to adjust for time differences was 8% and 5% for maximum SUVs and average SUVs ranging from 2 to 12.
In untreated breast cancer, the SUV at any time point approximately predicts the rate of change of SUV over time. A comparison method based on this finding appears feasible and may improve the usefulness of the SUV by providing a means of comparing SUV acquired at different times after injection.
本研究的目的是测量乳腺癌中（18）F-FDG PET标准化摄取值（SUV）随时间的变化，并检验一种针对临床实践中摄取测量时间适度变化进行调整的方法的可行性。
进行（18）F-FDG PET 60分钟动态成像，并在注射后约75分钟获取额外图像。对于20例新诊断、未治疗的局部晚期乳腺癌患者，计算病变内最大SUV和平均SUV，且分别进行血糖浓度校正和未校正的计算。对注射后27分钟开始的时间-活性曲线部分进行线性回归分析，以估计27至75分钟间隔内SUV每分钟的变化率。将SUV随时间的变化率与27至75分钟不同时间点获得的瞬时SUV进行比较。
在未治疗的乳腺癌中，（18）F-FDG SUV值在27分钟后大致呈线性变化，变化率为每分钟-0.02至0.15。此外，SUV变化率与注射后不同时间测量的瞬时SUV呈线性相关（r²范围为0.82至0.94；P<0.001）。利用该信息，建立了从注射到摄取测量时SUV随时间变化的经验线性模型。然后将该比较方法前瞻性地应用于初始分析未纳入的另一组20个局部晚期乳腺癌病变。对于最大SUV和平均SUV范围为2至12的情况，使用该方法调整时间差异的平均百分比误差分别为8%和5%。
在未治疗的乳腺癌中，任何时间点的SUV大致可预测SUV随时间的变化率。基于这一发现的比较方法似乎可行，并且通过提供一种比较注射后不同时间获得的SUV的方法，可能会提高SUV的实用性。
Zotero 插件